Medtronic

This earnings season may be starting to wind down, but there are still plenty of quarterly reports on the schedule. This week we will hear from more retailers, including Best Buy (NYSE: BBY), Lowe's (NYSE: LOW) and Tiffany (NYSE: TIF). Tech companies Dell (NASDAQ: DELL) and Hewlett-Packard (NYSE:...

While the fate of the 2010 health care reform law may rest in the hands of the Supreme Court, the nation's focus on health care has returned for the moment. For investors, the following health care picks all pay a dividend and have seen double-digit percentage growth in their share price since the...

For a holiday-shorted week, there will still be plenty for investors and analysts to mull over on the earnings front. Quarterly results from global tech company Hewlett-Packard (NYSE: HPQ), farm and construction equipment maker Deere & Co. (NYSE: DE) and food companies Campbell Soup (NYSE: CPB...

While the DJIA and S&P 500 dropped on today's opening, medical device makers MAKO Surgical (NASDAQ: MAKO) and Urologix (NYSE: ULGX) have reached new multiyear highs of $38.13 and $1.22 per share, respectively. MAKO Surgical reported last month that second-quarter revenue grew 81% year over...

The earnings season may be winding down, along with the summer, but this week will bring some more quarterly reports from retailers. Here's a quick rundown of what analysts expect to see from them. Bebe Stores (NASDAQ: BEBE): EPS up 50.0% to $0.04 (reports Thursday) Express (NYSE: EXPR): EPS up 46...

The markets ended the week closing lower two days in a row. Yet small cap biotech companies RTI Biologics (NASDAQ: RTIX) and STAAR Surgical (NASDAQ: STAA) rose to new 52-week highs of $3.75 and $7.08 per share, respectively, in Friday's trading session. RTI Biologics has been in a very strong...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

JP Morgan provided color on Medtronic (NYSE: MDT). In a research report published today, the rating agency commented on the criticism on the company's Infuse product. In the report, JP Morgan states, “Last Tuesday (6/28) The Spine Journal released a scathing criticism of Medtronic's Infuse....

Morgan Keegan provided color on Medtronic (NYSE: MDT). In a research report published today, Morgan Keegan commented on the problems in some research, which had been sponsored by Medtronic. In the report, Morgan Keegan states, “Review of 13 InFuse Studies identifies important failings, especially...

According to Piper Jaffray, Medtronic (NYSE: MDT) price target is $44. Piper Jaffray said that, while more negative focus on InFuse will likely continue to pressure spine division sales, the larger portion of MDT's spine business, core constructs, are trending upward. “Our price target of $44 is...